The companies inked a non-binding letter of intents yesterday. The proposed tie-up will be an all-stock transaction in which Oncotelic will become a wholly owned subsidiary of MabVax. The combined company, 75% owned by MabVax shareholders and 25% owned by Oncotelic shareholders, will do business as Oncotelic.
The deal may include at least $10M in new financing.
Subscribe for full text news in your inbox